Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document

Abstract

Background:

Hidradenitis suppurativa (HS) is a painful, debilitating, and poorly understood condition, which is suboptimally diagnosed, managed, and treated. Evidence supporting various treatment modalities is sparse.

Objectives:

To incorporate scientific evidence and expert opinions to develop useful guidance for the evaluation and management of patients with HS.

Methods:

An expert panel of Canadian dermatologists and surgeons developed statements and recommendations based on available evidence and clinical experience. The statements and recommendations were subjected to analysis and refinement by the panel, and voting was conducted using a modified Delphi technique with a prespecified cutoff agreement of 75%.

Results:

Ten specific statements and recommendations were accepted by the expert panel. These were grouped into 4 domains: diagnosis and assessment, treatment and management, comorbidities and a multidisciplinary approach, and education.

Conclusions:

These statements and recommendations will serve to increase awareness of HS and provide a framework for decisions involving diagnosis and management. Evidence suggests that antibacterial and anti–tumour necrosis factor therapies are effective in the treatment of HS. This is supported by the clinical experience of the authors. Further clinical research and the establishment of multidisciplinary management teams will continue to advance management of HS in Canada.

Keywords

hidradenitis suppurativa inflammatory nodules abscesses antibacterials anti–tumour necrosis factor therapies biologics multidisciplinary approach

Get full access to this article

View all access options for this article.

References

Deckers

Prens

. An update on medical treatment options for hidradenitis suppurativa. Drugs. 2016;76:215-229.

The Canadian Hidradenitis Suppurativa Foundation. www.hs-foundationcanada.org. Accessed June 13, 2017.

Zouboulis

Desai

Emtestam

et al . European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644.

Gulliver

Zouboulis

Prens

Jemec

Tzellos

. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343-351.

Van der Zee

Gulliver

. Medical treatments of hidradenitis suppurativa: more options, less evidence. Dermatol Clin. 2016;34:91-96.

Alavi

Kirsner

. Local wound care and topical management of hidradenitis suppurativa. J Am Dermatol. 2015;73:S55-S61.

Eubank

Mohtadi

Lafave

et al . Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. BMC Med Res Methodol. 2016;16:56.

Revuz

Jemec

GBE

. Diagnosing hidradenitis suppurativa. Dermatol Clin. 2016;34:1-5.

Alavi

Adam

Alhusayen

et al . Definition of moderate to severe hidradenitis suppurativa: a position paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF). J Cutan Med Surg. 2016;20(6):613-615.

10.

Kimball

. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434-1442.

11.

Alavi

. Discussion: what heals hidradenitis suppurativa: surgery, immunosuppression or both? Plast Reconstr Surg. 2016;138(3)(suppl):230S-231S.

12.

Ingram

Woo

Chua

et al . Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174(5):970-978.

13.

Clemmensen

. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22:325-328.

14.

Woodruff

Charlie

Leslie

. Hidradenitis suppurativa: a guide for the practicing physician. Mayo Clin Proc. 2015;90(12):1679-1693.

15.

Riis

Boer

Prens

et al . Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol. 2016;75(6):1151-1155.

16.

Jemec

Guérin

Kaminsky

Okun

Sundaram

. What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis. J Med Econ. 2016;19(7):710-717.

17.

Alhusayen

Shear

. Scientific evidence for the use of current traditional systemic therapies in the treatment of patients with hidradenitis suppurativa. J Acad Dermatol. 2015;73:S42-S46.

18.

Jemec

Wendelboe

. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971-974.

19.

Mendonca

Griffiths

. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154(5):977-978.

20.

Gener

Canoui-Poitrine

Revuz

et al . Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148-154.

21.

Bettoli

Zauli

Borghi

et al . Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28(1):125-126.

22.

Van der Zee

Boer

Prens

et al . The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219(2):143-147.

23.

Mortimer

Dawber

Gales

Moore

. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263-268.

24.

Joseph

Jayseelan

Ganapathi

et al . Hidradenitis suppurativa treated with finasteride. J Dermatol Treat. 2005;16(2):75-78.

25.

Blok

van Hattem

Jonlman

et al . Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168(2):243-252.

26.

Kimball

Kerdel

Adams

et al . Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846-855.

27.

Kimball

Okun

Williams

et al . Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434.

28.

Miller

Lynggaard

Lophaven

et al . A double-blind, controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:263-268.

29.

Grant

Gonzalez

Montgomery

et al . Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, cross-over trial. J Am Acad Dermatol. 2010;62:205-217.

30.

Adams

Yankura

Fogelberg

Anderson

. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501-504.

31.

Tzanetakou

Kanni

Giatrakou

et al . Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52-59.

32.

Van Rappard

Mekkes

Tzellos

. Randomized controlled trials for the treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34:69-80.

33.

Mahmoud

Tierney

Hexsel

et al . Prospective, controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium aluminium garnet laser. J Am Acad Dermatol. 2010;62:637-645.

34.

Buimer

Ankersmit

Wobbes

Klinkenbijl

. Surgical treatment of hidradenitis suppurativa with gentamycin sulphate: a prospective randomized study. Dermatol Surg. 2008;34:224-247.

35.

Highton

Chan

Khwaja

Laitung

. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg. 2011;128:459-465.

36.

Fadel

Tawfik

. New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. Clin Exp Dermatol. 2015;40:116-122.

37.

Angel

Ramasastry

Manders

et al . Beneficial effects staphage lysate in the treatment of chronic recurrent hidradenitis suppurativa. Surg Forum. 1987;38:111-112.

38.

Hessam

Sand

Gambichler

Bechara

. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2015;73(6):998-1005.

39.

Watters

Tredget

. Nutrition and wound healing. Can J CME. April 2002:65-74.

40.

Smith

Chao

Teitelbaum

. Painful hidradenitis suppurativa. Clin J Pain. 2010;26(5):435-444.

41.

World Health Organization. WHO’s pain relief ladder. 2009. http://www.who.int/cancer/palliative/painladder/en/. Accessed June 13, 2017.

42.

Esmann

Jemec

. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91:328-332.

43.

Fimmel

Zouboulis

. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatol Endocrinol. 2010;2(1):9-16.

44.

Alavi

Sibbald

. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol. 2015;16(1):61-65.

45.

Kim

Alavi

. Clinical features and patient outcomes of hidradenitis suppurativa: a cross-sectional retrospective study. J Cutan Med Surg. 2016;20(1):52-57.

46.

Jemec

GBE

. Efficacy and safety of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a phase 3, randomized, placebo-controlled trial. Abstract FC08.2. Presented at: 22nd Congress of the European Dermatology and Venereology (EADV) Meeting; October 2-6, 2013; Istanbul, Turkey.